Intarcia Ref. No. INT 004.10 USSN 10/004,118 PATENT

I hereby certify that this correspond	ATF. OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) lence is being facsimile transmitted to the Commissioner for Patents, United States No. 571-273-8300) on the date indicated.
	140. 37 (-273-6300) off the date indicated.
Jany R. Falran	
Signature	28 January 2008
Signature	Date of Transmittal

·	ENT AND TRADEMARK OFFICE
In Re Application of: Stanford Mark Moran	Confirmation No. 8022
Serial No.: 10/004,118	Art Unit: 1647
Filing Date: 30 October 2001	Examiner: Seharaseyon, J.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The information listed below may be material to the examination of the above-identified application. A completed Form PTO-1449 and copy of the cited reference accompany this paper.

Applicant request that the Examiner initial and return the form to indicate that the reference has been reviewed and made of record in the present application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

RECEIVED CENTRAL FAX GENTER Intarcia Ref. No. INT 004.10

USSN 10/004,118

PATENT

JAN 28 2008

Authorization to Charge Deposit Account:

6507809030

The Commissioner is hereby authorized to charge \$180.00 under 1.17(p) for Submission of an Information Disclosure Statement to Deposit Account No. 504212 (please reference docket number INT 004.10). No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number INT 004.10) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated: 28 January 2008

By:

Gary R. Fabian, Ph.D. Agent for Applicant Registration No. 33,875

any R Fabran

Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608

01/30/2008 VBUI11

00000007 504212

10004118

92 FC:1806

189.69 DA